Poly Medicure LtdQ1 FY26

Poly Medicure Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,638P/E: 54.6Market Cap: ₹17.5K CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

See what Poly Medicure Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No information is provided regarding the same in the latest conference call.

See what Poly Medicure Ltd management said on order book — free account, 30 seconds.

Capex plans

No information is provided regarding the same in the latest conference call.

Track Poly Medicure Ltd — get its next earnings analysis in your feed

How does Poly Medicure Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature
ThisPoly Medicure Ltd

How does Poly Medicure Ltd rank in Healthcare Equipment & Supplies?

Compare Poly Medicure Ltd against every Healthcare Equipment & Supplies company (Q1 FY26) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

Others in Healthcare Equipment & Supplies this season

  • Fischer Medical Ventures Ltd (Q2 FY25)

    EBITDA: ₹36.3 crore, a 45.5% year-on-year increase. Key concall takeaways from Fischer Medical Ventures Ltd's Q2 FY25 earnings call — and how it ranks against…

  • Fischer Medical Ventures Ltd (Q1 FY27)

    The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…

  • OSEL Devices Ltd (Q1 FY26)

    FY25 total income (revenue) was ₹18,660.07 lakhs, up 41% YoY from ₹13,268.52 lakhs in FY24. Key concall takeaways from OSEL Devices Ltd's Q1 FY26 earnings call…

  • Q-Line Biotech Ltd (Q4 FY26)

    Shift towards more manufacturing with gross margins of 60-65% for reagents supporting profitability improvement (Page 7, 6). Key concall takeaways from Q-Line…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →